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ABSTRACT 
One group of six male control rats [12 months old] and one group of six male rats of the same age, singularly main- 
tained in a cage, and treated with acetyl-L-carnitine-HCl [(gamma-trimethyl-beta-acetyl-butyrobetaine-HCl: Sigma-Tau 
code ST200 or ALCAR: 60 mg/kg/day[7]/po)] for six months were tested in the spatial learning/memory Morris maze- 
water task and for atrophy and cell loss in seven myelo- and cytostructurally defined basal forebrain (BF) cholinergic 
regions [Freddi et al., 2009]. Coronal sections 25 m thick were cut through the BF regions and processed every 200 
m for choline acetyltransferase (ChAT) immunohistochemistry. The ALCAR-treated rats had significantly shorter exit 
times on the Morris maze-water task test than the control rats (average ± SD 28.3 ± 12.4 s vs. 61.16 ± 4.67 s; t = 6.07, 
DOF = 10, P = 0.0001). Degenerative morphological changes in the BF ChAT-positive cells were observed in the sub-
stantia innominata pars anterior of the control rats but not in the treated animals (P < 0.05). In the BF, the counted and 
estimated average number of ChAT + cells in the 12-month-old ALCAR-treated rats (ChAT-ALCAR-12+ [Nos. 2,3,4]) 
was higher but not significantly (15.288 ± 3281) than that counted and estimated in the 12-month-old control rats 
[(ChAT-CT-12 [Nos. 1,2,3]) (11.508 ± 3868), t = 1.82, DOF = 10, P = 0.319]. In the substantia innominata pars poste- 
rior, the ChAT+ cells were significantly more numerous (P < 0.05) in the 12-month-old ALCAR-treated rats (ChAT- 
ALCAR-12 + [Nos. 2,3,4]) than in the control rats (ChAT-CT-12 [Nos. 1,2,3]). Above all, these results demonstrate 
that treatment with ALCAR from the age of 6 up to 12 months significantly attenuated spatial learning/memory impair- 
ment on the Morris maze-water behavioral task (P < 0.001) and also importantly reduced degeneration in size and nu- 
mber of cholinergic cells in the nucleus basalis magnocellularis of the BF. Accordingly, the surviving cholinergic neu- 
rons found in the BF of the ALCAR-treated rats might play an important role in modulating cortical activity and facili- 
tating processes of attention, learning and memory. 
 
Keywords: Acetyl-L-Carnitine-HCl; Ageing; Choline Acetyltransferase Neurons; Substantia Innominata; Morris 
Maze-Water Task 
1. Introduction 
Acetyl-L-carnitine ([ALCAR] gamma-trimethyl-beta-ace- 
tyl-butyrobetaine-hydrochloride, Sigma-Tau code: ST200) 
is the metabolically active form of acetylcarnitine present 
in the central nervous system (CNS). ALCAR acts as a 
shuttle for long-chain fatty acids between the cytoplasm 
and the mitochondria, is involved in the production of cel- 
lular energy and the removal of toxic accumulation of fat- 
ty acids from the mitochondria. It is actively transport- 
ed across the blood-brain barrier and displays affinities 
for GABAergic and L-glutamate carriers [1]. Acetyl-L-car- 
nitine is a source of acetyl groups and acts as a partial 
cholinergic agonist synergistically with ACh and L-glu- 
tamate, increasing the firing rate of rat neocortical neu- 
rons [2], thus working in the CNS [3-9]. 
Rodents present an age-related decline in nerve growth 
factor (NGF) and basal forebrain (BF) cholinergic neu- 
rons, as well as in learning and memory ability [10,11]. 
Acetyl-L-carnitine protects the CNS and NGF [8,9,12-13], 
improves cognitive deficits, and very importantly reduces 
rat mortality [14,15]. Rats and mice show an age-depen- 
dent decline in ACh and cell loss in the septo-hippocam- 
pal and BF regions [16-19]. Contrasting data about the 
age-dependent cholinergic cell BF decline have been re- 
ported by Horneberger et al. [20], who noted that aging 
causes a progressive shrinkage of AChE positive neurons 
in the BF nuclei, which was most pronounced in the nu- 
cleus basalis magnocellularis; however, the number of *Corresponding author. 
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cells remained unchanged. 
To date, no studies have investigated in 12-month-old 
rats, untreated and treated with ALCAR, for the severity 
and the extension of cholinergic cell loss in the seven my- 
elo- and cytoarchitecturally defined BF regions which 
comprise [15]: the medial septum (MS) and diagonal band 
of Broca (DBB), the magnocellular preoptic nucleus (MC- 
PO), the olfactory tubercle (Otu), the substantia innomi- 
nata pars anterior (SIa, also called the ventral pallidum), 
the substantia innominata pars posterior (SIp, also called 
the extended amygdala), and the globus pallidus (GP), 
where basal-cortical neurons projecting to the meso- and 
isocortex [21,22] intermingle with the BF cells projecting 
into the caudal hypothalamus [23]. 
Although cholinergic cells account for only 5% - 6% 
of the total population of the BF, this study focused on: 1) 
the topographical location and severity of cholinergic 
deficit in 12-month-old rats with impaired performance 
on the spatial/learning Morris water-maze test; and 2) the 
effect of acetyl-L-carnitine treatment on rats aged from 6 
to 12 months to see whether this neuropsychopharmaco- 
logical compound can significantly attenuate spatial lear- 
ning/memory impairment on the Morris maze-water task 
[13] and significantly reduce degeneration of the largest 
cholinergic neurons in the seven myelo- and cytoarchi-
tecturally defined BF regions [15,24-26]. 
2. Methods 
2.1. Animals 
All experiments were carried out in accordance with Di- 
rective 86/609/EEC regulating experimental animal care 
and with the aim to maximally reduce stress, suffering 
and the number of animals used [15,25]. 
Twelve male Sprague-Dawley Ico rats (OFA-SD-IOPS 
Caw) (IFFACredo, Italy) (age, 6 months; approximate 
body weight 545 ± 20 g) bought by Sigma-Tau (Rome, 
Italy) were singularly maintained in cages at the Sigma- 
Tau laboratory, given food and water ad libitum and kept 
in a 12/12 h light/dark cycle, at 22˚C ± 3˚C, humidity 50% 
± 15%, in a specific pathogen-free (SPF) area where they 
were checked regularly for common rat pathogens and 
general health so as to exclude pathological states which 
could interfere with the testing phase. 
Similar to Markowska et al. [14], the treatment group 
was six 6-month-old rats given 60 mg/kg of ALCAR 
[(gamma-trimethyl-beta-acetyl-butyrobetaine-HCl: Sig-ma- 
Tau code ST200)] in their drinking water every day a 
week for six months (ChAT-ALCAR-12: Nos. 1, 2, 3, 4, 
5, 6); the six control rats received only water and food ad 
libitum from the age of 6 to 12 months (ChAT-CT-12: 
Nos. 1, 2, 3, 4, 5, 6). The total volume of ALCAR solution 
was calculated on the basis of the animals’ daily water con- 
sumption, and the total amount of ALCAR given was 
calculated in relation to each animal’s weight [16]. To 
ensure that each animal received 60 mg/kg of ALCAR, 
both parameters were checked daily during the experi- 
ments. The concentration of ALCAR consumption was 
approximately 6% on mass basis. However, we do not 
know exactly the mortality rate of the colonies of rats 
treated with ALCAR at the Sigma-Tau laboratories at the 
Pomezia Research Centre (Rome, Italy). Markowska and 
co-authors reported that the mortality ratio of the rats, 
with about the same body weight, at the Gerontology Re- 
search Centre, at the Johns Hopkins University, Balti- 
more, and at the University of Colorado, was 2 - 3 rats 
out of 15 treated with 75 mg/kg/day/os of ALCAR [14] 
(see Table 2 and Figure 2). 
2.2. Behavioral Morris Water-Maze Test 
After six months of ALCAR treatment (or not), all twel- 
ve 12-month-old rats were tested, during daylight, for spa- 
tial learning/memory on the Morris water-maze task [27]. 
The test apparatus consisted of a large round plastic tank 
(130 cm in diameter and 45 cm high) filled to a depth of 
40 cm with 770 litres of water kept at 24˚C. The test ap- 
paratus was divided into four quadrants by four points 
positioned at equal distances along the edge and arbitrar- 
ily labelled North, South, East and West. A white escape 
platform (10 cm in diameter) was located 1 cm beneath 
the water surface in the middle of the NW quadrant, and 
kept at the same position in the pool at all times during 
the experiment. The pool was placed in a corner of a ro- 
om containing several extra-maze cues (objects) which 
the animals could use as reference points to locate the 
platform. Dried milk powder was added to the water to 
make it opaque. The day before each experiment, the plat- 
form was removed, the water was changed, and the rat 
was allowed to swim freely for 3 minutes so as to beco- 
me familiar with the surroundings. On test days the ani- 
mals were placed in the tank at one of the four different 
equidistant starting points along the edge and timed to 
see how long they took to reach the platform. After the 
rats had found the platform, they were left on it for 30 
seconds before beginning a new trial. Four trials(a,b,c,d) 
were carried out per session(s) [S1 + S2 + S3 + S4] [15]. 
The experiment was divided into two phases: an acquisi-
tion phase consisting of eight sessions, and a retention 
phase, presented in this study, consisting of four sessions. 
We calculated the average time (in s) that each animal 
took to climb onto the platform during the retention pha- 
se of four sessions [S1(a,b,c,d) + S2(a,b,c,d) + S3(a,b,c,d) + S4(a,b, 
c,d)]: the last test was performed before death by aortic 
perfusion. The average time needed to escape onto the 
platform (in seconds (s)) was statistically analyzed using 
two- and one-way ANOVA and post-hoc Student’s t-test 
multiple comparison of the means. 
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2.3. Surgery and Perfusion 
After completing the behavioral tests at the Sigma-Tau 
laboratory, the five control (ChAT-CT-12: Nos. 1,2,3,4,5 
(body weight, 713 ± 36.5 g) and the four ALCAR-treated 
(ChAT-ALCAR-12: Nos. 1, 2, 3, 4 (body weight, 730 ± 
73.5 g) male Sprague-Dawley Ico rats were anaesthetized 
with chloral hydrate (278 ± 15 mg/ip) for surgery and 
perfusion at the Medical School of the University of Mi- 
lan (Milan, Italy). One control rat (ChAT-CT-12: No. 6) 
and 2 ALCAR-treated rats (ChAT-ALCAR-12: Nos. 5, 6) 
were delivered to the Pharmacy School of the University 
of Milan (Milan, Italy) for another parallel study. 
As previously reported [15], the brains of the five con-
trol (ChAT-CT-12: Nos. 1,2,3,4,5 (body weight, 713 ± 
36.5 g) and the four ALCAR-treated (ChAT-ALCAR-12: 
Nos. 1, 2, 3, 4 (body weight, 730 ± 73.5 g) male Sprague- 
Dawley Ico rats were fixed by perfusion through the as- 
cending aorta, first with a phosphate buffered solution 
[(PBS; 0.1 M, pH 7.4, containing 20 mM MgCl2) (<100 
ml within 30 s)], then with a fixative solution containing 
3% paraformaldehyde, 0.2% picric acid and 0.05% glu- 
taraldehyde (pH 7.4) in 0.1 M PBS) (approximately 1000 
ml over 30 min), and finally with 10% sucrose PBS (pH 
7.4) (approximately 250 ml over 15 min). All solutions 
were perfused at a temperature between 10˚C and 18˚C. 
The brains were removed, cut into two coronal blocks, 
immersed overnight, and shaken at 4˚C in 30% sucrose/ 
PBS, then frozen at –50˚C in liquid freon and stored at 
–80˚C. 
2.4. Immunocytochemistry 
As previously published [15,21-24], coronal brain sec- 
tions 25 μm thick of the ChAT-CT-12+: Nos. 1,2,3 and 
of the ChAT-ALCAR-12+: Nos. 2,3,4 rats were cut on a 
freezing microtome and collected every 200 μm in PBS 
(pH 7.3). The sections were processed for visualization 
of choline acetyl transferase (ChAT+) labeling using the 
peroxidase antiperoxidase (PAP) technique with a ChAT 
monoclonal antibody (1:4) prepared in rats (Boehringer 
Mannheim, Germany). The ChAT antibody was obtained 
by fusing mouse myeloma cells (X63Ag8.653) with spleen 
cells of Wistar rats after immunization with highly puri-
fied choline acetyltransferase from pig brains. The sec-
tions were incubated overnight, first with the primary 
antibody, then with a rabbit anti-rat antibody (1:50, ICN, 
Italy) for 45 min, and finally with rat PAP (1:50 - 1:75) 
(Sternberger Monoclonals Inc., USA) for 45 min. The last 
two steps were repeated in a double-bridge procedure. 
The primary and secondary antibodies were diluted in Tris 
solution (TS, 0.1 M) containing 1% normal rabbit serum 
(NRbS) which was also used for rinses between incuba- 
tions. Before incubation, the sections were placed in TS 
containing a higher concentration of bovine serum albu- 
min (BSA 10%) for blocking. The peroxidase (PAP) was 
revealed by 6 min incubation with 0.05% 3',3' diamino- 
benzidine (DAB) and 0.01% hydrogen peroxidase (H2O2) 
in Tris water (TW). Control sections were incubated with- 
out the primary antibody and processed with the second- 
dary antiserum, PAP, and DAB. 
2.5. Estimation and Morphological Image  
Analysis of the ChAT+ Cells in the BF 
As previously reported [15,21-24], to map and estimate 
the BF ChAT-immunoreactive cells in the BF of the 3 
control (ChAT-CT-12+: Nos. 1, 2, 3) and of the 3 ALCAR- 
treated (ChAT-ALCAR-12+: Nos. 2, 3, 4) rats—where 
the perfusion and immunohistochemistry were best deve- 
loped—we used a Biocom image-analysis system (Bio-
com, Paris, France) with a computer-based atlas of cho-
linergic BF cell groups. The image-analysis system con-
sisted of a Leitz Dialux microscope equipped with an x/y 
movement-sensitive stage and a video camera (COHU) 
connected to a Compaq Deskpro/25 M computer. The 
atlas consisted of 6 templates (800 μm apart) extending 
from AP levels A10.9 - A6.9 through the BF regions, 
divided into seven contours distributed over more than 
one level. Labeled ChAT+ cells were mapped [ChAT-CT- 
12+: Nos. 1,2,3 and ChAT-ALCAR-12+: Nos. 2, 3, 4] or 
drawn [ChAT-CT-12+: No. 1 and ChAT-ALCAR-12+: 
No. 2] in the seven subregions of the BF by fitting each 
section to the appropriate atlas template at low power 
(2.5 × objective) and tracing or indicating the ChAT- 
CT-12+: Nos.1, 2, 3 + cells and the ChAT-ALCAR-12+: 
Nos. 2, 3, 4 + cells of the rats using a mouse-driven cur= 
sor at high power (40 × objective). 
2.6. Statistical Analysis 
As previously described [15,21-24], the morphometric 
measurements of the ChAT-CT-12+ and the ChAT-AL- 
CAR-12+ cell groups under study were averaged for ea- 
ch BF nucleus and are presented here, as previously de- 
scribed for 2 rats: one control (ChAT-CT-12+ No. 1) and 
one ALCAR-treated (ChAT-ALCAR-12+ No. 2) rat. Da- 
ta were analyzed with Student’s t-test. 
Abercrombie’s estimation of cholinergic cells has re- 
cently been demonstrated not to differ significantly from 
stereological estimation of cholinergic cells [24,25]. There- 
fore, we performed average cell counts per 3 rats from 
each group [ChAT-CT-12+: Nos. 1, 2, 3 and ChAT-AL- 
CAR-12+: Nos. 2, 3, 4] in the seven cyto- and myelos- 
tructurally defined BF regions [25] and computed the 
total numbers by using Abercrombie’s formula (Aber-
crombie 1946), viz. using the average morphometric mea- 
surements of the large diameters of the ChAT-CT-12+ 
(No. 1) and ChAT-ALCAR-12+ (No. 2) cells calculated 
from the longest diameter of the nuclei. 
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The computer-based maps through the BF were com- 
pleted for publication using the Corel Draw 8 software 
program. 
3. Results 
3.1. Morris Behavioral Water-Maze Test 
The average exit time in the last four sessions (S1(a,b,c,d) + 
S2(a,b,c,d) + S3(a,b,c,d) + S4(a,b,c,d)) of the final trials during 
the retention phase of spatial learning and memory con-
solidation of the Morris water-maze test [13], i.e., the 
time taken to reach the platform, was significantly grea- 
ter on average in the 12-month-old control rats [ChAT- 
CT-12+ (Nos. 1, 2, 3) (61.16 ± 4.67 (s)] than in the 12- 
month-old ALCAR-treated rats [ChAT-ALCAR-12+ (Nos. 
2,3,4) (28.30 ± 12.40 (s)] (Table 1). The control animals 
had consistently longer exit times. Prolonged ALCAR 
treatment of the rats, from the age of 6 to 12 months, very 
significantly attenuated the impairment in spatial learn- 
ing (P < 0.0001). Moreover, the exit times in the last four 
sessions of the final trial indicate that the aged ALCAR- 
treated rats showed the most significant drop in exit time 
in the last session [13] (see Table 1 and Figure 2). 
3.2. Localization of ChAT Basal Forebrain  
Neurons 
Stained BF sections: in the 12-month old controls [ChAT- 
CT-12+ (Nos. 1, 2, 3)] and in the ALCAR-treated [ChAT- 
ALCAR-12+ (Nos. 2, 3, 4)] rats, the cells containing ChAT 
were evident by a dark floccular brown staining pro- 
duced by DAB. As previously reported [24], ChAT+ cel-  
 
Table 1. Time taken by 12-month-old control rats (ChAT- 
CT-12; Nos. 1, 2, 3) and ALCAR-treated 12-month-old rats 
(ChAT-ALCAR-12; Nos. 2, 3, 4) to find the platform (sec- 
onds) on the Morris water-maze test.  
Groups Time taken to find the platform (seconds) 
 Trial Exit time (s) Exit time (s)
 S1(a,b,c,d) S2(a,b,c,d) S3(a,b,c,d) S4(a,b,c,d) 
Trial S1-S4
Mean  SD
Control      
ChAT-CT-12; Nos. 1, 2, 3 
Average 67.0 62.3 59.3 56.0 61.16 
SD 1.73 2.51 4.72 6.00 4.67 
      
ALCAR  
ChAT-ALCAR-12; Nos. 2, 3, 4 
Average 42.3 33.3 24.3 13.3 28.30 
SD 2.08 1.15 1.52 2.51 12.40 
1) Two-way ANOVA showed that the ALCAR-treated rats (ChAT-AL- 
CAR-12; Nos. 2, 3, 4) had significantly shorter exit times than the untreated 
control rats (ChAT-CT-12; Nos. 1, 2, 3): across groups (P = 0.0001), sections 
(P = 0.0001) and between group and sections (P = 0.0013); 2) One-way 
ANOVA for each group showed that all ALCAR-treated rats (ChAT-AL- 
CAR-12; Nos. 2, 3, 4) had significantly shorter exit times than the untreated 
control rats (ChAT-CT-12; Nos. 1, 2, 3) (P = 0.0001); 3) Rats in the same 
group (ChAT-CT-12; Nos. 1,2,3 and ChAT-ALCAR-12; Nos. 2, 3, 4) took 
approximately the same time to reach the platform. 
ls were examined only if they were visible as whole cells 
containing nuclei with at least 3 dendrites. 
In the BF, the ChAT+ cells in the control rats (ChAT- 
CT-12+: Nos. 1, 2, 4) (Figure 1) and the ChAT+ cells in 
the ALCAR-treated rats (ChAT-ALCAR-12: Nos. 2, 3, 4) 
(Figure 2) were distributed throughout the myelo-cyto- 
architectonic subregions: the medial septum (MS), the 
diagonal band of Broca (DBB), the magnocellular preop- 
tic nucleus (MCPO), the olfactory tubercle (OTu), the 
substantia innominata pars anterior (SIa), also called the 
ventral pallidum, the substantia innominata pars posterior 
(SIp), also called the sublenticular substantia innominata 
 
 
AAA: anterior amygdaloid area; ac: anterior commissure; Acb: accumbens 
nucleus; BLA: basolateral amygdaloid nucleus; BST: bed nucleus of the 
stria terminalis; CeA: central amygdaloid nucleus; CPu: caudate putamen; 
DBB: diagonal band of Broca nucleus; EP: entopeduncularis nucleus; f: 
fornix; GP: globus pallidus; ic: internal capsule; LH: lateral hypothalamus 
area; LOT: lateral olfactory tract; LPOA: lateral preoptic area; LS: lateral 
septum; MCPO: magno cellular preoptic nucleus; MeA: medial amygdaloid 
nucleus; MS: medial septum; oc: optic chiasm; ot: optic tract; OTu: olfac-
tory tubercle; Pir: piriform cortex; Ret: reticularis nucleus; SIa: substantia 
innominata pars anterior; SIp: substantia innominata pars posterior; sm: stria 
medullaris; SO: supra optic nucleus 
Figure 1. Computer atlas figure showing six levels of the BF. 
The contours of the major subregions were drawn with the 
aid of a computer image-analysis system (Biocom, Paris, Fr- 
ance). Distribution of ChAT+ cells in the ChAT-CT-12+ No. 
1 rat was directly mapped at high magnification (40×) on 
the atlas template. Each symbol represents one labeled cell. 
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AAA: anterior amygdaloid area; ac: anterior commissure; Acb: accumbens 
nucleus; BLA: basolateral amygdaloid nucleus; BST: bed nucleus of the 
stria terminalis; CeA: central amygdaloid nucleus; CPu: caudate putamen; 
DBB: diagonal band of Broca nucleus; EP: entopeduncularis nucleus; f: 
fornix; GP: globus pallidus; ic: internal capsule; LH: lateral hypothalamus 
area; LOT: lateral olfactory tract; LPOA: lateral preoptic area; LS: lateral 
septum; MCPO: magno cellular preoptic nucleus; MeA: medial amygdaloid 
nucleus; MS: medial septum; oc: optic chiasm; ot: optic tract; OTu: olfac-
tory tubercle; Pir: piriform cortex; Ret: reticularis nucleus; SIa: substantia 
innominata pars anterior; SIp: substantia innominata pars posterior; sm: stria 
medullaris; SO: supra optic nucleus 
Figure 2. Computer atlas figure showing six levels of the BF. 
The contours of the major subregions were drawn with 
the aid of a computer image-analysis system (Biocom, Paris, 
France). Distribution of ChAT+ cells in the ChAT-ALCAR- 
12+ No. 2 treated rat was directly mapped at high magnifica-
tion (40×) on the atlas template. Each symbol represents one 
labeled cell.  
 
or extended amygdala, and the globus pallidus (GP). 
Throughout the BF, the ChAT+ cells of the 12-month-old 
control and ALCAR-treated rats were found to be ori- 
ented according to the principal direction of the passing 
fibers within the seven BF subregions. 
The ChAT+ cells in the BF of the control rat [ChAT- 
CT-12 + (No. 1)] varied from small to medium in size, 
ranging from 11.9 to 21.9 µm in large diameter; they for- 
med a population with one mode, with an average large 
diameter of 16.8 ± 2.0 µm (Table 2).  
In the ALCAR-treated rat [ChAT-ALCAR-12+ (No. 
2)] (Table 2), the ChAT+ cells varied in size and shape, 
being fusiform, oval or polygonal and correspondingly 
bi- or multipolar across the different BF regions. Meas- 
urements of the cell soma showed that the ChAT+ cells 
varied from small to large, ranging from 9 to 32.5 µm in 
large diameter, and formed a population with one mode. 
Indeed, the majority of the ChAT+ cells had medium to 
large-sized neurons with a long diameter of 17.9 ± 1.8 µm. 
In summary, the average large diameter of the ChAT+ 
cells recorded in the control rat [ChAT-CT-12+ (No. 1)] 
was significantly smaller than the average of the large 
diameter of the ChAT+ cells measured in the ALCAR- 
treated rat [ChAT-ALCAR-12+ (No. 2)] (Table 2). Al-
though the cell population of the ChAT-CT-12+ (No. 1) 
and of the ChAT-ALCAR-12+ (No. 2) overlapped in 
surface area and diameter, the population of the ChAT- 
CT-12+ (No. 1) was significantly (P < 0.05) smaller than 
that of the ChAT+ cells of the ALCAR-treated rat [ChAT- 
ALCAR-12+ (No. 2)] (Table 2).  
Throughout the BF, the ChAT+ cells were more nu-
merous in the ALCAR-treated rats [(ChAT-ALCAR-12+ 
(Nos. 2,3,4)] than in the control rats [ChAT-CT-12+ 
(Nos. 1,2,3)] (15.288 ± 3281 vs. 11.508 ± 3868, respec-
tively) (Table 3). 
3.3. Regional Characterization and Distribution 
of ChAT+ Cells 
Located rostrally in the deeper inner ring of the BF where 
the transverse fiber systems sweep beneath the accum- 
bens-striatum and pars anterior of the anterior commis- 
sure, ChAT+ cells are located within the anterior portion 
of the substantia innominata (SIa). The ChAT+ cells in 
the subcommisural SIa are frequently elongated, multi- 
polar neurons that commonly lie with their long axes 
parallel to the transverse fibers that travel throughout this 
 
Table 2. Morphometry of choline acetyltransferase-positive 
(ChAT+) neurons in the basal forebrain of one aged 12- 
month-old control rat (ChAT-CT-12+ # 1) and one AL- 
CAR-treated rat (ChAT-ALCAR-12+ # 2).  
ChAT-CT-12+ No. 1    







SIa 5 8.1 ± 2.2 14.0 ± 0.9* 99.2 ± 16.4
BF 35 10.0 ± 2.4 16.8 ± 2.0* 134.5 ± 37.1
ChAT-ALCAR-12+ No. 2    







SIa 5 8.5 ± 2.4 15.3 ± 0.4* 100.8 ± 14.7
BF 36 10.3 ± 2.3 17.9 ± 1.8* 140.2 ± 40.7
1) Measurements in μm and μm2 (Mean ± SD) in the basal forebrain (right 
site of the brain) for ChAT+ cells in one animal from each group: aged 
control rat (ChAT-CT-12+ No. 1) and one aged ALCAR-treated rat (ChAT- 
ALCAR-12+ No. 2) (16, 22, 23,24,25); 2) Student’s t-test for each meas-
urement showed ChAT-CT-12+ cells differed significantly from ChAT- 
ALCAR-12+ cells in structure and measurements indicated (P < 0.05*). 
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Table 3. Average crude cell counts and average estimated 
total cholinergic viz. choline acetyltransferase-positive (Ch- 
AT+) neurons in the basal forebrain of 12-month-old con- 
trol rats (ChAT-CT-12+ Nos. 1, 2, 3) and of ALCAR-treated 
rats (ChAT-ALCAR-12+ Nos. 2, 3, 4). 
Structure Sites sampled 
Crude 
Counts ± SD 
Estimated  
Totals ± SD 
Probability of 
t-test 
ChAT-CT-12 + Nos. 1, 2, 3   
SIp 2 73 ± SD 5* 1387 ± 95* P < 0.05 
Total BF 6 601 ± 202 11,508 ± 3868 n.s. 
ChAT-ALCAR-12+ Nos. 2, 3, 4   
SIp 2 103 ± 19*  1894 ± 349*  
BF 6 820 ± 176 15,288 ± 3281  
1) Labeled ChAT+ cells on the right side of the brain were plotted from 
A10.9 to A6.9 (16, 22, 23, 24, 25) and their number tabulated for each struc- 
ture in 25-μm thick sections at intervals of 800 μm. The average crude cell 
count (±SD) and the estimated total number for each structure are presented; 
2) The averages of the estimated totals were obtained by multiplying the cell 
count by the number of sections per interval (32), corrected for the average 
BF cell size of each structure and 25-μm thick sections at intervals of 800 
μm, using Abercrombie’s formula (16, 22, 23, 24, 25); 3) (*) Student’s t-test 
showed that there was a significant number of ChAT+ neurons in the sub- 
stantia innominata pars posterior of the ALCAR- treated rats (ChAT-AL- 
CAR-12+ Nos. 2, 3, 4) in comparison with the control rats (ChAT-CT-12+ 
Nos. 1, 2, 3). 
 
region. The ChAT+ neurons in the SIa of the 12-mon- 
th-old control rats were significantly smaller than those 
in the ALCAR-treated rats, measuring 14.0 ± 0.9 µm vs. 
15.3 ± 0.4 µm in long diameter on average (P < 0.05) [24]. 
Caudally, behind the crossing of the anterior commis- 
sure, and dorsally, deep in the magnocellular preoptic nu- 
cleus where transverse fibers sweep under the globus pal- 
lidus and caudate putamen, ChAT+ cells are distributed 
through the posterior portion of the substantia innominata. 
Rostrally, the cluster of ChAT cells are oriented in paral- 
lel with passing fibers of the stria medullaris and inferior 
thalamic peduncle, which turn dorsomedially into the 
rostral pole of the thalamus, and also with the perforating 
blood vessels which traverse the magnocellular preoptic 
nucleus to continue through the substantia innominata 
into the lentiform nucleus. In such aggregates the ChAT+ 
cells are multipolar neurons that form vertically oriented 
clusters by parallel alignment of soma and dendrites. We 
observed more ChAT+ cells in the SIp of the ALCAR- 
treated rats [(ChAT-ALCAR-12+ (Nos. 2, 3, 4)] than in 
the control rats [ChAT-CT-12+ (Nos. 1, 2, 3)] (on average 
1894 vs. 1387, respectively) (P < 0.05) [24]. 
4. Discussion 
4.1. Morris Behavioral Water-Maze Task 
A possible limitation to this study is that we did not ev- 
aluate or record the motor performance or the distance 
traveled in cm or the time spent in the correct quadrant or 
the representative trajectories of the two rat groups dur- 
ing swimming performance to find the platform. How- 
ever, the similarity between the Morris water-maze es- 
cape latency times for the aged control and treated rats in 
this study belong to the category of the so-called “inter- 
mediate performer rats” as classified by Taglialatela et al. 
[13,28] (see Figures 1 and 2). 
The behavioral findings of this study strongly indicate 
and confirm that prolonged treatment with ALCAR can 
very significantly (P < 0.0001) improve spatial learning 
and memory on the Morris water-maze test [Freddi et al., 
2009]. This study confirmed that the 12-month-old con- 
trol rats with impaired spatial learning and memory per- 
formance on the Morris water-maze test [13,28] had sig- 
nificantly smaller and fewer BF cholinergic neurons than 
the ALCAR-treated rats [16]. It has been claimed that AL- 
CAR affects the cholinergic central systems through its 
manifold properties, namely, by increasing the catalyst of 
L-carnitine acylation to acetyl-L-carnitine, serving as a 
precursor for acetylcholine, maximizing energy produc-
tion, promoting cellular membrane stability, counteract-
ing membrane changes, particularly those related to age, 
and by supporting physiological cellular functioning at 
the mitochondrial level [15,13,28,29]. We suggest that 
ALCAR treatments from an age of 6 to 12 months can, 
with various different degrees of impact, counteract age- 
dependent neurodegenerative central and cognitive func- 
tion changes—and perhaps peripheral motor pathologies 
which are considerably accelerated during aging. AL- 
CAR treatment during ageing seems to strongly influence 
the activity of the cholinergic basal complex, so as to fa- 
cilitate cortical activation, attention, learning and mne- 
monic processes. 
4.2. Morphology and Estimation of BF  
ChAT+ cells 
Our morphological analysis focused on the myelo- and 
cytostructural BF regions where cholinergic cells are lo- 
cated [25,26]. Our results suggest that the average values 
of the morphological parameters of the ChAT-immuno- 
reactive neurons in the BF of 12-month-old control rats 
(ChAT-CT-12) were lower than those of the cholinergic 
cells observed in the BF of young rats [24] and lower 
than the cholinergic neurons observed projecting into the 
meso- and isocortex [22 but similar to the cholinergic 
cells projecting into the caudal hypothalamus [23]. Inter- 
estingly, the large diameter of the ChAT+ cells in the BF 
of the ALCAR-treated 12-month-old rats was similar to 
the large diameter of the ChAT+ cells calculated in 518 
cholinergic cells in the young control rats [24]. 
Accurate morphological analysis revealed that the av- 
erage size of ChAT+ neurons in the anterior portion of the 
substantia innominata of the spatial learning/memory- 
impaired control rats was significantly smaller than that 
in the 12-month-old ALCAR-treated rats. The average of 
the large diameter of the ChAT+ neurons of the substantia 
Copyright © 2012 SciRes.                                                                                 JBBS 
R. FREDDI  ET  AL. 24 
innominata pars anterior found in the 12-monthold AL- 
CAR-treated rats was similar to the average large diame- 
ter of the ChAT+ cells in the substantia innominata pars 
anterior of the young rats [24]. 
Accurate morphological analysis and estimation of the 
ChAT cells number revealed that the average estimated 
number of ChAT+ cells throughout the substantia inno- 
minata pars posterior of the spatial learning/memory -im- 
paired control rats was significantly lower than that esti-
mated in the 12-month-old ALCAR treated rats (1387 vs. 
1894, respectively; P < 0.05). The number of choliner- 
gic cells estimated in the ALCAR-treated rats was nearly 
the same as that estimated in the substantia innominata 
pars posterior in the younger rats (approximately 2182) 
[24].  
Interestingly, ALCAR treatment from the age of 6 to 
12 months was found to preserve a large number of cho- 
linergic neurons in the BF of the rats (15, 288). This es- 
timated value is similar to that in the young rats (18, 236, 
[24]) and higher than that reported in 21-month-old AL- 
CAR-treated rats [8,15]. 
Despite differences in immunocytochemical techni- 
ques and rat strain and sex, the results of this study do 
partly agree with previous reports that: 1) there is a re- 
duction in NGF+/putative-cholinergic neurons in the BF 
of rats with longer latency on the spatial water-maze task 
[10,11] aging causes progressive shrinkage of acetyl cho- 
linoesterase (AChE)-positive neurons in the BF nuclei 
[20]; 3) there was a 30% - 50% reduction in ChAT and 
AChE activities in the BF [29]; 4) there was a significant 
reduction in AChE-positive cells in the BF of 24- and 
31-month old Wistar rats [16]. 
To sumarize, treatment with ALCAR in rats aged be- 
tween 6 and 12 month can significantly boost perform- 
ance on the spatial learning/memory Morris water-maze 
task and may importantly and significantly prevent the 
loss of the magnocellular cholinergic neurons and the 
change in size within some cholinergic subgroups. The 
largest diameter of BF cholinergic cells in the 12-month 
old ALCAR-treated rats was similar to that of the ChAT+ 
cells in the BF [24], yet similar to those of the choliner- 
gic cells projecting into the prefrontal and parietal corti- 
ces [21]. 
In conclusion, this study confirms that early chronic 
ALCAR treatment, from the age of 6 months, may better 
rescue cholinergic neurotransmission which is known to 
decline with age [15,22,24,25]. 
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